Lifestyle
- Maintain adequate hydration
- Avoid smoking
- Engage in regular aerobic exercise
Hematocrit · HCT · PCV
Hematocrit quantifies the proportion of blood volume that is occupied by red blood cells.
Reference ranges can vary based on age, sex, and altitude. Typically higher in males and lower in females.
Hematocrit (HCT) is a blood biomarker that measures the proportion of blood volume occupied by red blood cells. It is a crucial component of the complete blood count (CBC) and provides insight into the oxygen-carrying capacity of the blood. Researchers have found that hematocrit levels are indicative of various physiological and pathological states. Clinically, hematocrit is important for diagnosing and monitoring conditions such as anemia, polycythemia, dehydration, and blood loss. Elevated hematocrit levels can reflect conditions like polycythemia vera or chronic obstructive pulmonary disease (COPD), while low levels may indicate anemia or overhydration. In the context of athletic performance and biohacking, hematocrit is relevant as it can influence endurance and oxygen delivery to tissues. Athletes may seek to optimize hematocrit levels to enhance performance, although this must be done cautiously to avoid health risks. Hematocrit levels can be influenced by factors such as hydration status, altitude, and certain medications. Researchers observed that time-of-day variations and recent physical activity can also affect hematocrit readings, making standardized testing conditions important for accurate assessment.
Klinische Bedeutung
Elevated hematocrit levels may indicate dehydration, polycythemia vera, or chronic hypoxia. Reduced hematocrit levels can suggest anemia, blood loss, or overhydration.
Progressively rising hematocrit values may suggest dehydration or polycythemia. Re-test in 4 weeks if outside the optimal range.
Progressively falling hematocrit values may indicate anemia or blood loss.
Re-test Interval
4 weeks if outside optimal range
Note:
Consult a physician before starting iron supplementation, especially if not diagnosed with iron deficiency.
Hematocrit levels can vary with diurnal changes; morning measurements are often preferred.
Testing Frequency
Annually for healthy adults, more frequently if monitoring a known condition.
May affect
Current research suggests that reference ranges for hematocrit in the context of hematopoietic cell transplantation (HCT) remain poorly defined, particularly regarding optimal targets for predicting complications like graft-versus-host disease (GVHD). Researchers have not yet established the impact of confounding factors such as inflammation and concurrent infections on hematocrit levels post-HCT. Additionally, clinical questions remain unanswered about the role of hematocrit as a prognostic biomarker for long-term outcomes in HCT recipients.
798
Total Citations
24
Human/RCT
3.0
Avg. Influence
2025
Latest
Researchers developed a biomarker algorithm based on blood samples taken seven days after HCT to predict severe graft-versus-host disease (GVHD) and nonrelapse mortality. The algorithm successfully identified high-risk patients, demonstrating its potential for improving patient management.
Researchers aimed to identify biomarkers for chronic graft-versus-host disease (cGVHD) after HCT. They found a four-biomarker panel that effectively predicts cGVHD diagnosis and severity, which could aid in patient stratification and management.
This study focused on identifying blood biomarkers for acute graft-versus-host disease (GVHD) to improve diagnosis and management. Researchers observed that combining novel biomarkers with traditional cytokines may enhance predictive capabilities for patient outcomes.
This review summarized recent proteomics approaches aimed at identifying plasma biomarkers for acute graft-versus-host disease (GVHD). Researchers noted the potential for these biomarkers to provide diagnostic, prognostic, and predictive value, which could enhance therapeutic decisions for patients.
This review discussed the interpretation of laboratory tests in transgender individuals undergoing hormone therapy. Researchers highlighted the need to adjust reference ranges for hematocrit and other tests based on the individual's affirmed gender to improve clinical care and outcomes.
This position paper addressed the management of splenomegaly in myelofibrosis patients before allogeneic HCT. Researchers found that significant splenic enlargement is linked to higher risks of graft failure and mortality, highlighting the need for assessment and potential treatment of splenomegaly prior to transplantation.
This review focused on the definitions and clinical implications of biomarkers in graft-versus-host disease (GVHD) following hematopoietic cell transplantation (HCT). Researchers found that while many biomarkers have been identified, none are yet qualified for clinical use. The study emphasizes the need for clarity in biomarker definitions to improve clinical management of GVHD.
This study examined the complications related to liver disease following hematopoietic cell transplantation (HCT). Researchers found that acute liver dysfunction is often indicated by early liver function test results, with common causes including graft-versus-host disease and infections. Prompt diagnosis through laboratory tests and imaging is crucial for effective management.
Researchers conducted a matched case-control study to investigate the association between idiopathic intracranial hypertension and anemia. They found no significant differences in complete blood count values between patients with idiopathic intracranial hypertension and controls.
Researchers analyzed treatment patterns in polycythemia vera (PV) patients and found that maintaining hematocrit levels below 45% is crucial to prevent thrombotic events. The study revealed that a significant portion of patients had suboptimal HCT control, with many experiencing thrombotic events post-treatment.
Research publications about Hämatokrit over time
9totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer